Amy Raskin, CIO at Chevy Chase Trust, joins CNBC's "Halftime Report" to detail her latest portfolio moves. Sometimes a good ...

U.S. officials approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin.

CNBC’s Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the FDA's approval of the company's non-opioid painkiller pill Journavx, a new ...

Having worked with global companies such as Teleperformance, Vertex, and MIBS, he brings his expertise in ... NFL SLIMETIME PRESENTS NICKELODEON'S GAME CHANGERS: BRAND-NEW SPECIAL FOR KIDS & FAMILIES ...

Plus: A new non-opioid painkiller, the wave of lawsuits against Trump EOs, a key vote for RFK Jr., a big radiopharma deal and more.

While it's next to impossible to know how many opioids entered the state illegally in 2023, we do know that just under 1.7 ...

Get ready for a cool, jazzy, spell-binding February. Musicians from New York and the Midwest are bringing innovative concerts ...

Vertex Pharmaceuticals Incorporated today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided its full year 2025 financial guidance.

Students learned that many of these careers can be pursued with or without a college degree. Warren County Court Judge and ...

The 988 line was supposed to anchor a crisis system that gave people “someone to call, someone to come, somewhere to go.” It hasn't happened.

The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare sector as a whole. This time last year, the biotech ...